 NASHVILLE, Tenn., June 21, 2021 PRNewswire --Cumberland Pharmaceuticals Inc. NASDAQ: CPIX, a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ telavancin in treating secondary bacterial infections in COVID-19 patients particularly those with other significant health problems, such as obesity, diabetes and heart disease. 